Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?

Ovarian cancer is one of the most lethal gynaecological malignancies worldwide. Despite high success rates following first time treatment, this heterogenous disease is prone to recurrence. Oncogenic activity of receptor tyrosine kinases is believed to drive the progression of ovarian cancer. Here we...

Descripción completa

Detalles Bibliográficos
Autores principales: Rendell, Aimee, Thomas-Bland, Isobel, McCuish, Lee, Taylor, Christopher, Binju, Mudra, Yu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495728/
https://www.ncbi.nlm.nih.gov/pubmed/36140214
http://dx.doi.org/10.3390/biomedicines10092113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495728/
https://www.ncbi.nlm.nih.gov/pubmed/36140214
http://dx.doi.org/10.3390/biomedicines10092113

Ejemplares similares